BI 2536

Catalog No.S1109

Molecular Weight(MW): 521.66

BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.

Cited by 56 Publications

Nature, 2017, 548(7668):466-470

PubMed: 28759889 ( click the link to review the publication )

Cell, 2011, 4(10):1087-96

PubMed: 22078882 ( click the link to review the publication )

Cancer Discov, 2014, 4(11):1281-9

PubMed: 25107667 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: ( click the link to review the publication )

Nat Cell Biol, 2015, 17(1):31-43

PubMed: 25503564 ( click the link to review the publication )

Nat Cell Biol, 2011, 13(10):1265-71

PubMed: 21874008 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2017

PubMed: 26829474 ( click the link to review the publication )

Nat Commun, 2016, 7:10818

PubMed: 26912231 ( click the link to review the publication )

Nat Commun, 2015, 10.1038/ncomms8217

PubMed: 26147444 ( click the link to review the publication )

Nat Commun, 2015, 6:6891

PubMed: 25922916 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(12):3211-21

PubMed: 24771642 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(32):13026-31

PubMed: 23878225 ( click the link to review the publication )
Cancer Res, 2015, 75(2):405-14

PubMed: 25480943 ( click the link to review the publication )

Cancer Res, 2014, 74(20):5878-90

PubMed: 25125659 ( click the link to review the publication )

Cancer Res, 2013, 73(22):6722-33

PubMed: 24101154 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Cancer Res, 2011, 71(17):5659-69

PubMed: 21693658 ( click the link to review the publication )

J Cell Biol, 2011, 193(6):1083-99

PubMed: 21646404 ( click the link to review the publication )

J Control Release, 2015, 204:20-29

PubMed: ( click the link to review the publication )

Oncogene, 2013, 10.1038/onc.2013.518

PubMed: 24317508 ( click the link to review the publication )

Oncogene, 2011, 30(46):4666-77

PubMed: 21602893 ( click the link to review the publication )

Cancer Lett, 2015, 357(2):591-601

PubMed: 25524551 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(9):1886-95

PubMed: 21654832 ( click the link to review the publication )

Sci Signal, 2018, 11(530)

PubMed: 29764992 ( click the link to review the publication )
Br J Cancer, 2013, 110(2):510-9

PubMed: 24327015 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 14(4):946-60

PubMed: 25659891 ( click the link to review the publication )

J Neurochem, 2015, 10.1111/jnc.13085

PubMed: 25727910 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(5):1160-71

PubMed: 24568369 ( click the link to review the publication )

Gynecol Oncol, 2013, 128(3):461-9

PubMed: 23146687 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 13(5):1054-66

PubMed: 24748653 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M116.722751

PubMed: 27226586 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M115.712745

PubMed: 27325694 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26344-56

PubMed: 25100726 ( click the link to review the publication )

J Biol Chem, 2014, 289(18):12313-29

PubMed: 24634213 ( click the link to review the publication )

J Biol Chem, 2014, 289,14066-14074

PubMed: ( click the link to review the publication )
J Biol Chem, 2012, 287(6):4376-85

PubMed: 22184120 ( click the link to review the publication )

J Biol Chem, 2012, 287(21):17088-99

PubMed: 22467873 ( click the link to review the publication )

Mol Biol Cell, 2015, 26(3):440-52

PubMed: ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2013, 54(13):8353-63

PubMed: 24366665 ( click the link to review the publication )

Cell Cycle, 2015, 14(2):219-31

PubMed: 25607646 ( click the link to review the publication )

Cell Cycle, 2014, 13(2):303-14

PubMed: 24247149 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3867-77

PubMed: 25558830 ( click the link to review the publication )

Biosci Rep, 2014, 34(3)

PubMed: 24844881 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115228

PubMed: 25542032 ( click the link to review the publication )

PLoS One, 2014, 8(10):e77053

PubMed: 24204733 ( click the link to review the publication )

PLoS One, 2012, 7(6):e38838

PubMed: 22701722 ( click the link to review the publication )

J Biomol Screen, 2013, 18(1):54-66

PubMed: 22923784 ( click the link to review the publication )
Biol Open, 2013, 2(5):479-86

PubMed: 23789096 ( click the link to review the publication )

Biotechniques, 2012, 10.2144/000113866

PubMed: ( click the link to review the publication )

Oncotarget, 2017, 8(23):37633-37645

PubMed: 28430578 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2315-30

PubMed: 25537513 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5275-91

PubMed: 25779659 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2315-30

PubMed: 25537513 ( click the link to review the publication )

Oncotarget, 2014, 5(3):667-78

PubMed: 24525428 ( click the link to review the publication )

The University of Queensland, 2014, Fawzi Faisal A. Bokhari

PubMed: ( click the link to review the publication )

13 Customer Reviews

(C) HeLa cells were treated with inhibitors of Aurora B (hesperadin), Aurora A (Aurora A inhibitor I), CDK1 (roscovitine), or PLK1 (BI2536) for 2 hours before immunostaining for tubulin and phosphorylated RV[S/T]F (p-RV[S/T]F). Nuclei are indicated with DAPI. Control cells were not treated with any inhibitor. More than 50 cells were imaged for each condition in three independent experiments. Scale bar, 20 μm.

Science, 2018, 11(530), doi: 10.1126/scisignal.aai8669. BI 2536 purchased from Selleck.

Comparison between Genetic Ablation of Cdc20 and Current Mitotic Drugs (C) Transformed Cdc20(lox/lox); RERT(+/Cre) MEFs were subcutaneously injected into the two flanks of SCID mice, and tumors were scored every 2-3 days.These mice were injected i.p. (three injections per week) with 4-OHT or mitotic drugs (taxol, vincristine, and BI2536) when tumors reached about 200 mm³ of volume (day 11; arrow) (n = 8 mice per group). (D) Representative images of these fibrosarcomas 3 days after injection with 4-OHT (to generate Cdc20(D/D) cells), BI2536, or taxol. These mice were injected with 10 μM BrdU to score DNA replication. CA3, immunodetection of active caspase 3. Scale bars, 50 or 10 μM (insets).

Cancer Cell 2010 18, 641–654. BI 2536 purchased from Selleck.
(a,b) RPE1 cells transfected with control or either of two B56-PP2A siRNA pools (1, 2) were incubated in MG132 (10µM, 15 min), followed by the addition of BI2536 (40 nM) or DMSO for 45 min. (a) The frequency of mitotic cells with few or absent cold-stable K-bres . (b) Maximum-intensity projection of tubulin (green) and an overlay with kinetochores (CREST, red) in B56-PP2A-siRNA (pool 2) cells treated with DMSO or BI2536 (40 nM). Insets are 3 enlargement of the optical sections spanning the outlined centromeres.

Nat Cell Biol 2011 13, 1265-71. BI 2536 purchased from Selleck.

(a) HeLa Tet-On cells were treated with the indicated siRNAs, arrested in mitosis using 500 nM nocodazole (Noc) and 10 μM MG132, and then treated with or without BI 2536. The endogenous Cdc20 was immunoprecipitated from these cells and blotted with the indicated antibodies. The mitotic index of each sample is indicated below each lane. The bottom graph shows the quantification of the Cdc20-pS92 signal normalized to the total Cdc20 signal (mean±range; n=2 independent experiments).

Nat Commun, 2016, 7:10818. BI 2536 purchased from Selleck.
Treatment with BI 2536 induces cell-cycle arrest in NB TICs and aberrant accumulation of cyclin B1 and p21. C, expression of cyclin B1 and p21 was assessed in NB88R2 following 16 and 24-hour treatment with different doses of BI 2536 (10, 30, and 100 nmol/L). ERK1 (extracellular signal regulated kinase 1) was used as the loading control. D, inhibition of PLK1 was assessed by in vitro kinase assay following treatment of NB88R2 for 3 hours with BI 2536.

Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

Treatment with BI 2536 induces cell death via apoptosis. A,treatment with BI 2536 (10, 30, and 100 nmol/L) reduces viable cell numbers as assessed by trypan blue exclusion. B, representative Western blot demonstrating accumulation of cleaved PARP following treatment with 10 nmol/L BI 2536.

Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.
BI 2536 inhibits NB tumor growth in vivo. A and B, NOD/SCID mice bearing 50- to100-mm³ tumors were injected intravenously with either vehicle (0.1N HCl per saline) or 12.5 to 25 mg/kg BI 2536 for 2 consecutive days a week, for a total of 3 cycles.Two independent experiments were performed in each case with 5 animals per group. Representative tumor growth data are shown.

Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.

animals with 50- to 100-mm³ tumors were randomized into 4 groups: group 1 injected intravenously with vehicle (0.1N HCl per saline), group 2 injected intravenously with 12.5 mg/kg of BI 2536 (2 consecutive days, 3 cycles), group 3 injected i.p. with 10 mg/kg of irinotecan (3 doses total, 3 days apart), and group 4 injected with BI 2536 and irinotecan. Both representative tumor growth data and a Kaplan-Meyer survival plot are shown.

Cancer Res 2011 71, 1385-1395. BI 2536 purchased from Selleck.
Plk-1 knockdown and inhibition by BI 2536 and viability of human melanoma cell lines M14 and WM-115 as demonstrated by MTT assay. Experiments were performed in triplicate. One representative experiment is shown. *P<0.001, ANOVA test with Tukey’s post-test. ANOVA, analysis of variance; MTT, 3-(4,5 dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Plk-1, polo-like kinase 1; siRNA, small-interfering RNA; WB, western blot.

J Invest Dermatol 2011 131, 1886–1895. BI 2536 purchased from Selleck.

Western blot analysis of the expression and phosphorylation of Plk1, and phosphorylation of Myt1 in the CSC-like cells after treatment with BI 2536 for 24 and 48 hours, respectively.

Oncotarget, 2017, 8(23):37633-37645. BI 2536 purchased from Selleck.
Cells with decreased GRK5 expression are more sensitive to PLK1 inhibition.A , shown is cell death in control or GRK5-shRNA stably transfected cells after 72 h of treatment with 0-120 nM BI 2536 as determined by trypan blue exclusion (n = 6).B , shown is cell death in control or GRK5-shRNA stably transfected cells after 72 h treatment with 0 –120 nM GSK461364, as determined by trypan blue exclusion ( n = 4).

J Biol Chem 2012 287(21), 17088-99. BI 2536 purchased from Selleck.

J Biomol Screen 2013 18(1), 54-66. BI 2536 purchased from Selleck.
Example dose response curves of the PLK-1 inhibitor BI-2536. During the large dose response study for each reference compounds 8 dilutions were tested. Curves for IC50 determination for two independent experiments for the PLK1 inhibitor BI-2536 are displayed. This inhibitor is also used to achieve the LC values. IC50 has been determined with 7.48 +/- 0.09 log [M] and 6.75 +/- 0.21 log [M]. Correlating assay performance data are displayed in Suppl. Fig. 5.

J Biomol Screen 2013 18(1), 54-66. BI 2536 purchased from Selleck.

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Description

BI2536 is a potent Plk1 inhibitor with IC50 of 0.83 nM in a cell-free assay. It shows 4- and 11-fold greater selectivity against Plk2 and Plk3. Phase 2.

Features

The first potent and selective Plk1 inhibitor that induces all hallmarks of Plk1 inhibition.

Targets

PLK1 ^[1] (Cell-free assay)	PLK2 ^[1] (Cell-free assay)	PLK3 ^[1] (Cell-free assay)
0.83 nM	3.5 nM	9.0 nM

In vitro

BI 2536 blocks the activities of Plk2 and Plk3 to a slightly lesser extent with IC50 of 3.5 nM and 9.0 nM, respectively. In HeLa cells, BI 2536 treatment ranging from 10-100 nM leads to the blocking of the recruitment of γ-tubulin and phosphorylation of Apc6 at mitotic centrosomes, inhibition of cohesin release from chromosome arms, induction of monopolar spindles, as well as a range of other mitotic processes that are known to depend on Plk1. BI 2536 treatment leads to the HeLa cells arrested in G2/M, subsequently a sub-G1 DNA peak indicative of DNA breakdown and apoptosis, and accumulated cleaved PARP p85 fragments in a concentration-dependent manner. BI 2536 inhibits the growth of a panel of 32 human cancer cell lines with EC50 of 2-25 nM, while blocking the proliferation of exponentially growing hTERT-RPE1, human umbilical vein endothelial cells (HUVECs), and normal rat kidney (NRK) cells with EC50 of 12-31 nM. ^[1] Plk1 inhibition by BI 2536 reduces the growth and viability of anaplastic thyroid carcinoma (ATC) cells such as CAL62, OCUT-1, SW1736, 8505C, and ACT-1 with EC50 values of 1.4-5.6 nM. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
PSN1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XmWmlEPTB;MD6wNFc4PiEQvF2=	M4Dnb3NCVkeHUh?=
ACN	M2\4Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NV24V3V3UUN3ME2wMlAxQDR\|IN88US=>	M3vWRnNCVkeHUh?=
TE-8	NH\wPFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTBwMEC5OFEh\|ryP	MmLHV2FPT0WU
LC-2-ad	NUf3VlVrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3fIWWlEPTB;MD6wNVA6OyEQvF2=	NGPrfoNUSU6JRWK=
ALL-PO	M1O3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTBwMEGzJO69VQ>?	MmTUV2FPT0WU
EW-16	Mn33S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWTJR\|UxRTBwMEGzN\|Yh\|ryP	MULTRW5ITVJ?
KM12	MkPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlH4TWM2OD1yLkCxN\|Q5KM7:TR?=	NUn0OHc{W0GQR1XS
GI-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zJWWlEPTB;MD6wNVM5OyEQvF2=	M2X5T3NCVkeHUh?=
LS-411N	MnzlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGDCdJJKSzVyPUCuNFE1ODdizszN	NXrBOVR6W0GQR1XS
ES8	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HKV2lEPTB;MD6wNVQ6PCEQvF2=	Mo[2V2FPT0WU
SNU-C2B	NIjjSXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHWzXItKSzVyPUCuNFE2OjZizszN	MmXLV2FPT0WU
CESS	Ml;yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2facGlEPTB;MD6wNVYxOiEQvF2=	NEPKdFhUSU6JRWK=
697	M4LnSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvSdIVNUUN3ME2wMlAyPjZ6IN88US=>	MULTRW5ITVJ?
NCI-H1963	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MknSTWM2OD1yLkCxOlc{KM7:TR?=	NU[0V3Y4W0GQR1XS
IA-LM	MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGXy[ZVKSzVyPUCuNFE3QDhizszN	NHfhNYpUSU6JRWK=
SW954	NFrWeWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYrJR\|UxRTBwMEG3NFUh\|ryP	MlXYV2FPT0WU
RL95-2	MnvuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXuyc2tzUUN3ME2wMlAyPzN6IN88US=>	M{m4O3NCVkeHUh?=
LXF-289	NWruOoo2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWjFco9HUUN3ME2wMlAyPzdizszN	M{jMVXNCVkeHUh?=
OCUB-M	NGflZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVPJR\|UxRTBwMEG4NlYh\|ryP	NEHLNohUSU6JRWK=
RKO	Mnj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\nVGlEPTB;MD6wNVk5PyEQvF2=	MWrTRW5ITVJ?
LOUCY	Mon4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTBwMEKwOUDPxE1?	NEDWN2dUSU6JRWK=
NOS-1	M{TxeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYfJR\|UxRTBwMEKwPVMh\|ryP	NF\vXXRUSU6JRWK=
A4-Fuk	M2nvPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3mVlJKSzVyPUCuNFIzOThizszN	NVi1b4t3W0GQR1XS
A388	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVnWdXpDUUN3ME2wMlAzOjJ5IN88US=>	MonwV2FPT0WU
TE-9	M1TvTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULidodzUUN3ME2wMlAzOjZzIN88US=>	Mkn1V2FPT0WU
KURAMOCHI	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoG1TWM2OD1yLkCyNlg2KM7:TR?=	NH7MVpNUSU6JRWK=
KALS-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fQbGlEPTB;MD6wNlM{QCEQvF2=	NWrhNZZzW0GQR1XS
HOP-62	M4nUdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoK4TWM2OD1yLkCyOFIh\|ryP	NVPXO2hwW0GQR1XS
RPMI-8402	M{joPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWO2e3F6UUN3ME2wMlAzPTB6IN88US=>	M4[1bXNCVkeHUh?=
TE-1	NFLUTnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX;JR\|UxRTBwMEK1NVIh\|ryP	NH\JR3pUSU6JRWK=
CCRF-CEM	NUTHdlIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjOWJdKSzVyPUCuNFI2PDNizszN	NHHnNFhUSU6JRWK=
HUTU-80	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3n5bGlEPTB;MD6wNlYzPCEQvF2=	MYXTRW5ITVJ?
NCI-H1648	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTBwMEK2OFch\|ryP	NVnZdYVsW0GQR1XS
HCE-4	M1T5bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX\JR\|UxRTBwMEK2PFIh\|ryP	NYTSVIFJW0GQR1XS
ETK-1	M1;EZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mln6TWM2OD1yLkCyO\|M3KM7:TR?=	M3PpcXNCVkeHUh?=
TE-15	NX7vUJh4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIj0[JdKSzVyPUCuNFI4OzhizszN	MnX5V2FPT0WU
BE-13	M1;k[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEKzUoZKSzVyPUCuNFI4PCEQvF2=	NWLjcpBHW0GQR1XS
KE-37	M1XWZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVrJR\|UxRTBwMEK3OFEh\|ryP	NYnUe\|dyW0GQR1XS
NCI-H1355	NYTtXYdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWLXeZlYUUN3ME2wMlAzPzh\|IN88US=>	M3TFT3NCVkeHUh?=
TE-11	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHzmZVlKSzVyPUCuNFI5ODlizszN	NH\y[m9USU6JRWK=
BL-70	Mn3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;PUVhKSzVyPUCuNFI5PTdizszN	NHnxdVVUSU6JRWK=
ES6	M1[ySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH\kUVFKSzVyPUCuNFI5QDFizszN	NH3YZ4RUSU6JRWK=
GT3TKB	NHXSOXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2S0dWlEPTB;MD6wNlk2OyEQvF2=	NGiySmVUSU6JRWK=
LB647-SCLC	MkHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUnITGVSUUN3ME2wMlA{OTl3IN88US=>	NWrZ[JFIW0GQR1XS
NB13	MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHT4WoRKSzVyPUCuNFM{OTZizszN	M4jLSHNCVkeHUh?=
ST486	NF3nPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTBwMEOzN\|ch\|ryP	M1nrc3NCVkeHUh?=
NCI-H82	NETxSWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX3zZ\|ZxUUN3ME2wMlA{OzR\|IN88US=>	MnHBV2FPT0WU
NTERA-S-cl-D1	NWLmNlByT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXPofolEUUN3ME2wMlA{Ozl7IN88US=>	MUHTRW5ITVJ?
ES4	NVGxbINJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4XyUGlEPTB;MD6wN\|Q3OyEQvF2=	NF3NfFFUSU6JRWK=
SK-NEP-1	NG\5NWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGHiW2hKSzVyPUCuNFM1QTlizszN	Mn\kV2FPT0WU
Becker	Mkf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmm3TWM2OD1yLkCzOVU2KM7:TR?=	MXrTRW5ITVJ?
A101D	NGTLTZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHmXZlRUUN3ME2wMlA{PzR6IN88US=>	MUXTRW5ITVJ?
SK-UT-1	M4nMVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3rTWM2OD1yLkCzO\|c1KM7:TR?=	MYDTRW5ITVJ?
SW982	NFjWdnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPNSVNXUUN3ME2wMlA{PzlizszN	NXXVTI5sW0GQR1XS
TE-10	NVXRO2N6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFj0OW1KSzVyPUCuNFQxPDZizszN	NITJeZdUSU6JRWK=
OVCAR-4	MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\CWmlEPTB;MD6wOFA2QSEQvF2=	NITRd5ZUSU6JRWK=
KP-N-YS	NWS3c4hVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4[5VGlEPTB;MD6wOFA5PSEQvF2=	MWfTRW5ITVJ?
BL-41	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkTjTWM2OD1yLkC0NVI2KM7:TR?=	MnrDV2FPT0WU
MZ1-PC	NVPyZXRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlz3TWM2OD1yLkC0NVI4KM7:TR?=	NHzOOWJUSU6JRWK=
PF-382	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1jERmlEPTB;MD6wOFE6QCEQvF2=	NUmzNYhLW0GQR1XS
MOLT-13	NWfCcJMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3f3fmlEPTB;MD6wOFI{QCEQvF2=	MU\TRW5ITVJ?
HCC1599	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXWzO4xNUUN3ME2wMlA1OjV6IN88US=>	M1iwXHNCVkeHUh?=
IST-MEL1	NI\jT\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoXRTWM2OD1yLkC0OFQzKM7:TR?=	Mk\IV2FPT0WU
LU-139	NYLBSpp{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Moi1TWM2OD1yLkC0OFQzKM7:TR?=	MlnjV2FPT0WU
MS-1	MoniS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3fKXWlEPTB;MD6wOFcxOSEQvF2=	MoDBV2FPT0WU
MFH-ino	NEW5RnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1;yW2lEPTB;MD6wOVAxOyEQvF2=	MVnTRW5ITVJ?
IMR-5	MnL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\2TWM2OD1yLkC1NFIyKM7:TR?=	NGCyOJJUSU6JRWK=
TE-5	M3rQSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHPTWM2OD1yLkC1NFY{KM7:TR?=	MV3TRW5ITVJ?
DJM-1	M2G4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIfTR4RKSzVyPUCuNFUyPDJizszN	M16yPHNCVkeHUh?=
NB17	M3T6c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{fJXWlEPTB;MD6wOVIxPyEQvF2=	MlnQV2FPT0WU
KARPAS-45	M{TmWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3W5NWlEPTB;MD6wOVM2QCEQvF2=	NFz5cpBUSU6JRWK=
TGBC1TKB	NVWxOoo5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTBwMEW0NFUh\|ryP	M1TTbXNCVkeHUh?=
ML-2	MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrkTWM2OD1yLkC1OFE1KM7:TR?=	M2Tr[nNCVkeHUh?=
no-10	NHmxNVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlrkTWM2OD1yLkC1OFc1KM7:TR?=	MoXzV2FPT0WU
CTV-1	M17QXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2f2ZmlEPTB;MD6wOVUxOiEQvF2=	MXnTRW5ITVJ?
SJSA-1	NIHrbmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnP1TWM2OD1yLkC1OVIh\|ryP	NVHHPFBnW0GQR1XS
HC-1	NWOxcW56T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX2zSmdbUUN3ME2wMlA2PTl5IN88US=>	NFPoXJpUSU6JRWK=
TE-12	M3nxcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX7JR\|UxRTBwMEW2NVMh\|ryP	NEXueHFUSU6JRWK=
KY821	NWfYcW1[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml7mTWM2OD1yLkC1OlMzKM7:TR?=	MYfTRW5ITVJ?
TALL-1	M3rKd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MW\JR\|UxRTBwMEW3NFgh\|ryP	MkH4V2FPT0WU
DEL	M1zrT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWL0WoJ4UUN3ME2wMlA2PzB7IN88US=>	M1\FOnNCVkeHUh?=
TE-6	M1nWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTBwMEW3NlIh\|ryP	Mle1V2FPT0WU
SK-LMS-1	MonwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPQSpJKSzVyPUCuNFU5ODVizszN	Mm\NV2FPT0WU
EW-1	NFTlWldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPuTWM2OD1yLkC1PFM4KM7:TR?=	MX\TRW5ITVJ?
8-MG-BA	NECzUmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkD0TWM2OD1yLkC1PFUyKM7:TR?=	M4TuWHNCVkeHUh?=
NALM-6	M4TmSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTGNpU2UUN3ME2wMlA2QTd\|IN88US=>	NFHnN2hUSU6JRWK=
LB771-HNC	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVfJR\|UxRTBwMEW5O\|kh\|ryP	MmfMV2FPT0WU
HT-144	M1Wydmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYXJR\|UxRTBwME[xN{DPxE1?	MVPTRW5ITVJ?
KM-H2	MljLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVLjOnl{UUN3ME2wMlA3OjJzIN88US=>	NEe4NJVUSU6JRWK=
SF268	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHjzfnpKSzVyPUCuNFYzQDZizszN	NYjCN2RkW0GQR1XS
RS4-11	MoDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTBwME[zNFQh\|ryP	MWrTRW5ITVJ?
MHH-PREB-1	MnTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfFUnVKSzVyPUCuNFY{OTlizszN	Ml23V2FPT0WU
ATN-1	M4CwUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGX1dolKSzVyPUCuNFY{PDVizszN	MW\TRW5ITVJ?
BB30-HNC	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXvUTGpoUUN3ME2wMlA3PDN4IN88US=>	MX3TRW5ITVJ?
CPC-N	NELsTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVXVfFhIUUN3ME2wMlA3PTJ2IN88US=>	MoraV2FPT0WU
NB1	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTBwME[2NVMh\|ryP	M1LXPHNCVkeHUh?=
KS-1	Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mmm0TWM2OD1yLkC2O\|Q5KM7:TR?=	NGP4SHVUSU6JRWK=
RXF393	Mk\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYj5e5ZlUUN3ME2wMlA3PzZ2IN88US=>	M{W3TnNCVkeHUh?=
IST-SL2	M{\2bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MULJR\|UxRTBwMEewNFQh\|ryP	M1zaS3NCVkeHUh?=
GI-ME-N	NH;RTGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHPUTFhKSzVyPUCuNFczQDZizszN	NFLicndUSU6JRWK=
VA-ES-BJ	NGXNWlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkPWTWM2OD1yLkC3OFc2KM7:TR?=	MUTTRW5ITVJ?
NCI-H1581	NXLJUpluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3TNT2lEPTB;MD6wO\|Q4QCEQvF2=	Mlm1V2FPT0WU
U-266	NYruWWxRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PmTGlEPTB;MD6wO\|Q6PyEQvF2=	NFXu[3NUSU6JRWK=
DMS-114	M4TLbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1m1WWlEPTB;MD6wO\|UzQCEQvF2=	MmjVV2FPT0WU
NCI-H187	M2LoNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnXTWM2OD1yLkC3O\|I3KM7:TR?=	MU\TRW5ITVJ?
SW962	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUnJR\|UxRTBwMEe4N\|kh\|ryP	M3S1bHNCVkeHUh?=
MONO-MAC-6	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXTJR\|UxRTBwMEe5PFYh\|ryP	NX3DbYI3W0GQR1XS
MOLT-16	NYPCUlI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYnHOllHUUN3ME2wMlA5OTJzIN88US=>	MYrTRW5ITVJ?
KNS-42	M{fhUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3XSemlEPTB;MD6wPFE3OSEQvF2=	MoD4V2FPT0WU
CMK	M{C1emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWru[4J6UUN3ME2wMlA5OjJ3IN88US=>	MUPTRW5ITVJ?
Ramos-2G6-4C10	M{XISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmLQTWM2OD1yLkC4NlI2KM7:TR?=	NFnQUY5USU6JRWK=
Daudi	MlfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTBwMEiyOVYh\|ryP	MoK4V2FPT0WU
NCI-H510A	NXvvdIJxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MorFTWM2OD1yLkC4N\|M3KM7:TR?=	NF3VbYZUSU6JRWK=
LB831-BLC	M2PuWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jPemlEPTB;MD6wPFU3OSEQvF2=	MmnEV2FPT0WU
HEL	NHzxcnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPJR\|UxRTBwMEi2Olgh\|ryP	MmT6V2FPT0WU
LU-134-A	NHPyOYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1nyOWlEPTB;MD6wPFcxQCEQvF2=	MnvJV2FPT0WU
NCI-H1694	M{jTc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVzJR\|UxRTBwMEi3OFQh\|ryP	MmW0V2FPT0WU
KGN	NXK1TYpzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4O0bmlEPTB;MD6wPFc2QSEQvF2=	NYfjXpMxW0GQR1XS
A253	MnjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVjJR\|UxRTBwMEi4NlIh\|ryP	NInobXVUSU6JRWK=
DG-75	NV\icIdmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmLETWM2OD1yLkC4PVIzKM7:TR?=	M{jrZXNCVkeHUh?=
MOLT-4	Mn:5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTBwMEi5PFMh\|ryP	MmPpV2FPT0WU
NCI-SNU-5	M1LBZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HBOWlEPTB;MD6wPVI2QCEQvF2=	NYTWO2toW0GQR1XS
ONS-76	NVrl[lN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Moq4TWM2OD1yLkC5Nlc3KM7:TR?=	M4rBNXNCVkeHUh?=
NCI-H446	MoP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTBwMEm0OlIh\|ryP	MWfTRW5ITVJ?
COR-L279	MlPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV;JR\|UxRTBwMEm1OVYh\|ryP	NVr6XmJnW0GQR1XS
Calu-6	M2[3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnqzTWM2OD1yLkC5OVk5KM7:TR?=	NUP6eIFiW0GQR1XS
BC-3	M{LESWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTBwMEm2OlIh\|ryP	MX;TRW5ITVJ?
NCI-H2126	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYjJR\|UxRTBwMEm3PVEh\|ryP	M1zx[3NCVkeHUh?=
NCI-H1882	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mlv3TWM2OD1yLkC5PFA6KM7:TR?=	M2Kxd3NCVkeHUh?=
BB65-RCC	NYnmRZlyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml3BTWM2OD1yLkGwNlk1KM7:TR?=	MYXTRW5ITVJ?
DU-4475	NXPiXpd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVHJR\|UxRTBwMUC0NFch\|ryP	MVPTRW5ITVJ?
NCI-H526	M{[5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TZUmlEPTB;MD6xNFQ1KM7:TR?=	MojFV2FPT0WU
NEC8	NFnB[ZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmCyTWM2OD1yLkGwOVI2KM7:TR?=	MXzTRW5ITVJ?
NCI-H1304	M4jlb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYTSTlV2UUN3ME2wMlExPTl2IN88US=>	NXHHeoJ[W0GQR1XS
L-540	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoX4TWM2OD1yLkGwO\|A5KM7:TR?=	NHfrZ3hUSU6JRWK=
NCI-SNU-16	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVy3ZpJDUUN3ME2wMlExPzR{IN88US=>	NWTDXodDW0GQR1XS
HD-MY-Z	Mn7LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2\wNWlEPTB;MD6xNFg2PiEQvF2=	NVLOc3JLW0GQR1XS
K-562	Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVryTnZPUUN3ME2wMlExQDV6IN88US=>	MonMV2FPT0WU
JAR	M4W5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4qyd2lEPTB;MD6xNFkzPSEQvF2=	MkXaV2FPT0WU
MZ2-MEL	Mm\wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn\1TWM2OD1yLkGxNFUh\|ryP	NFnu[VlUSU6JRWK=
L-363	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTBwMUGwO\|kh\|ryP	Mn;IV2FPT0WU
BV-173	M4GxdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHfhNZlKSzVyPUCuNVEzPDNizszN	NETGU2FUSU6JRWK=
NCI-H524	NU\xeoZvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXJTWM2OD1yLkGxNlc1KM7:TR?=	Ml;1V2FPT0WU
EoL-1-cell	Moj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XRSmlEPTB;MD6xNVY4OiEQvF2=	NEDacZJUSU6JRWK=
K052	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUHJR\|UxRTBwMUG3NVIh\|ryP	MYrTRW5ITVJ?
TK10	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPtR2NKSzVyPUCuNVE4OjhizszN	NHr4S3FUSU6JRWK=
KU812	M175e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3LNXFKSzVyPUCuNVIxPDRizszN	NYfMZ3JpW0GQR1XS
RPMI-8226	M3vtWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M362c2lEPTB;MD6xNlA2OiEQvF2=	MWfTRW5ITVJ?
MZ7-mel	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTBwMUKyN\|ch\|ryP	M4fWTnNCVkeHUh?=
SK-PN-DW	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkPOTWM2OD1yLkGyNlg4KM7:TR?=	NVTPcWJQW0GQR1XS
SR	NF[0THFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1XwOGlEPTB;MD6xNlQ1OSEQvF2=	M1rzTXNCVkeHUh?=
RPMI-6666	M322PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1X0NWlEPTB;MD6xNlc1OyEQvF2=	MXjTRW5ITVJ?
no-11	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH7mWGJKSzVyPUCuNVI5PjlizszN	NXPmNpJGW0GQR1XS
EW-3	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3fjd2lEPTB;MD6xNlg6OyEQvF2=	NVjFfXRKW0GQR1XS
LAMA-84	NWC1OnFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnsTWM2OD1yLkGzNVg4KM7:TR?=	MnThV2FPT0WU
HT	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3LEXGlEPTB;MD6xN\|U4PCEQvF2=	NG[xPI9USU6JRWK=
KP-N-RT-BM-1	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml3GTWM2OD1yLkGzOlEzKM7:TR?=	NVfyfJRtW0GQR1XS
NCI-H747	NI\NU5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTBwMUO3JO69VQ>?	MonwV2FPT0WU
NCCIT	NYjaUVJoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnjjTWM2OD1yLkGzPVM6KM7:TR?=	M3SwWHNCVkeHUh?=
MLMA	NWnqVJNzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mkn5TWM2OD1yLkG0NVY4KM7:TR?=	MkDOV2FPT0WU
LP-1	MnXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoL0TWM2OD1yLkG0NlQh\|ryP	M3u3THNCVkeHUh?=
CAL-148	M1HyOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIOzTFJKSzVyPUCuNVQ1QDNizszN	NV[0TVZCW0GQR1XS
GB-1	MlTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\ScGlEPTB;MD6xOFUzPiEQvF2=	MmDZV2FPT0WU
COR-L88	NGXHfWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWLJR\|UxRTBwMUS4NFIh\|ryP	M4LON3NCVkeHUh?=
NKM-1	NYn1VGRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTBwMUS5NFYh\|ryP	NXLjRZpzW0GQR1XS
NB5	NVfNeWVkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXLXZ\|ZRUUN3ME2wMlE2PDZ{IN88US=>	MYjTRW5ITVJ?
SH-4	NGLIZpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTBwMUW0OlYh\|ryP	M1HncXNCVkeHUh?=
EM-2	MnTxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXX[GNUUUN3ME2wMlE2PDZ5IN88US=>	MlLRV2FPT0WU
TGBC24TKB	MmnjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHTXc21KSzVyPUCuNVU3PTlizszN	M2Xm[nNCVkeHUh?=
SCLC-21H	M3nIbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX3JR\|UxRTBwMUW3NFIh\|ryP	NILyRolUSU6JRWK=
COLO-684	NEC2bFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTBwMUW3NlEh\|ryP	MXPTRW5ITVJ?
KINGS-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFe2V3hKSzVyPUCuNVU6OSEQvF2=	MYXTRW5ITVJ?
LS-123	NFrhVZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHWTZBKSzVyPUCuNVU6OTdizszN	NFvnVZZUSU6JRWK=
MC116	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfXTWM2OD1yLkG2NVU5KM7:TR?=	NV[4bXFwW0GQR1XS
SU-DHL-1	M1LkR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTBwMU[yNFYh\|ryP	MnLGV2FPT0WU
NCI-H64	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfxTWM2OD1yLkG2N\|Q4KM7:TR?=	Ml;KV2FPT0WU
HCE-T	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYf3UnVTUUN3ME2wMlE3PTB2IN88US=>	NWjSWFU5W0GQR1XS
LOXIMVI	NUjrTIQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlPTTWM2OD1yLkG2PVQ6KM7:TR?=	NXTHe5lmW0GQR1XS
ARH-77	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3wbmpKSzVyPUCuNVc{PzlizszN	MljWV2FPT0WU
DOHH-2	M{\qRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUXtb4pCUUN3ME2wMlE4Pjd{IN88US=>	NYjQbmhWW0GQR1XS
COLO-320-HSR	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4n5SWlEPTB;MD6xPFE2PCEQvF2=	NWCySZlsW0GQR1XS
NB6	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYKweXBrUUN3ME2wMlE5PTZ4IN88US=>	M3XOUHNCVkeHUh?=
L-428	NVvwN4duT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjscYFKSzVyPUCuNVg5OTNizszN	NV2wW4xHW0GQR1XS
SNB75	NEC5ZpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPZVGdwUUN3ME2wMlE5QDJ2IN88US=>	MWrTRW5ITVJ?
NCI-H2141	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXjJR\|UxRTBwMUmwNVEh\|ryP	M1PxbnNCVkeHUh?=
KARPAS-299	NGS0cotIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFu2OXhKSzVyPUCuNVkzPDFizszN	NUTTNpYzW0GQR1XS
LC4-1	M3q3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7vTWM2OD1yLkG5OVAzKM7:TR?=	MmX5V2FPT0WU
UACC-257	NFznOWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MU\JR\|UxRTBwMUm5OFch\|ryP	M2XwcnNCVkeHUh?=
EVSA-T	NWrGcmRKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTBwMkCzNVIh\|ryP	MUTTRW5ITVJ?
JiyoyeP-2003	NHnrcFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVrxU\|Z5UUN3ME2wMlIxPDd5IN88US=>	M1ziR3NCVkeHUh?=
NCI-H720	NEewZZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX7aTHRVUUN3ME2wMlIxPTJ3IN88US=>	MXzTRW5ITVJ?
GAK	NGHk[GxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTBwMkGxPFkh\|ryP	MnfyV2FPT0WU
HH	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFjsOmNKSzVyPUCuNlE1ODVizszN	NFe3SHdUSU6JRWK=
NCI-H1436	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XqWWlEPTB;MD6yNVQ3PCEQvF2=	MY\TRW5ITVJ?
GR-ST	NHn4b4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYLOOWt4UUN3ME2wMlIyPDh6IN88US=>	MlXIV2FPT0WU
BC-1	NFrxdItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTBwMkK2NVYh\|ryP	M{\Zc3NCVkeHUh?=
SIG-M5	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4XacGlEPTB;MD6yNlczPyEQvF2=	M3;NXXNCVkeHUh?=
NCI-H345	MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYHJR\|UxRTBwMkO4NFUh\|ryP	Ml:5V2FPT0WU
OPM-2	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVzJR\|UxRTBwMkO4PFIh\|ryP	M3jVN3NCVkeHUh?=
LB1047-RCC	MlXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYLxWo8xUUN3ME2wMlI1PDFizszN	Mmi2V2FPT0WU
CTB-1	NFzCV2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4rqZmlEPTB;MD6yOFQ6OyEQvF2=	NX7Pe5pHW0GQR1XS
A3-KAW	NILN[W1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH3qZnNKSzVyPUCuNlU{PDFizszN	MXLTRW5ITVJ?
SF126	M1vTRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoLMTWM2OD1yLkK1N\|g{KM7:TR?=	NY\FWpVuW0GQR1XS
KARPAS-422	MkfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVLCbJZzUUN3ME2wMlI2PDN3IN88US=>	MUDTRW5ITVJ?
MEG-01	M{DIR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTBwMkW2O\|Mh\|ryP	NHf1WoJUSU6JRWK=
NCI-H209	Ml\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXL6dFZMUUN3ME2wMlI3Ozd2IN88US=>	M4XZVnNCVkeHUh?=
SBC-1	NX64PGpHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXrMeYt[UUN3ME2wMlI3PSEQvF2=	M1vmNHNCVkeHUh?=
K5	NWWxbZd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPKTWM2OD1yLkK2PVg1KM7:TR?=	NW\tN\|dOW0GQR1XS
QIMR-WIL	MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWXzPJNyUUN3ME2wMlI4OTV3IN88US=>	NYjNWmxSW0GQR1XS
NMC-G1	MojsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXjiXoJRUUN3ME2wMlI5OjF5IN88US=>	MlnVV2FPT0WU
IST-MES1	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M17IZWlEPTB;MD6yPVI{QCEQvF2=	MknZV2FPT0WU
SW684	M3P1ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYTJR\|UxRTBwM{CwOFch\|ryP	M4nufHNCVkeHUh?=
MV-4-11	NXfP[WhST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIXXZ2ZKSzVyPUCuN\|A4QDhizszN	NV32Z5p6W0GQR1XS
LAN-6	NFfuOlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmKyTWM2OD1yLkOxOVczKM7:TR?=	NH3uXWhUSU6JRWK=
RH-1	M2W2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3fPd2lEPTB;MD6zNVg4OSEQvF2=	M4DCdnNCVkeHUh?=
CP66-MEL	MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LFV2lEPTB;MD6zNVg4QCEQvF2=	M4DEc3NCVkeHUh?=
EC-GI-10	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTBwM{K5PFch\|ryP	MWnTRW5ITVJ?
GDM-1	MmH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljiTWM2OD1yLkOzNFU6KM7:TR?=	MnXYV2FPT0WU
IST-SL1	M3TkV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXfLeZZYUUN3ME2wMlM1QTF2IN88US=>	NEDRfZFUSU6JRWK=
KMOE-2	NWrGWZZoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4GyUGlEPTB;MD6zOVE4PSEQvF2=	NHHXcnhUSU6JRWK=
OS-RC-2	NWfwXmN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3\mUGlEPTB;MD6zOVU1PCEQvF2=	NVnSNYdCW0GQR1XS
HDLM-2	M3ThfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUXIcotGUUN3ME2wMlM4QDF2IN88US=>	MYDTRW5ITVJ?
DSH1	NXyxe3dnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXzTGtKSzVyPUCuN\|g3OzFizszN	MnGyV2FPT0WU
LS-1034	NWX4W2xnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofNTWM2OD1yLkO4PVU1KM7:TR?=	M1j4UXNCVkeHUh?=
LB373-MEL-D	Moe4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHfQco5KSzVyPUCuN\|kyQTdizszN	NHnDXYFUSU6JRWK=
GOTO	NHrYO4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVfofI1lUUN3ME2wMlQzOTF6IN88US=>	NHHZOmdUSU6JRWK=
MRK-nu-1	NWDqVZNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTBwNEKyNFUh\|ryP	M1vqTHNCVkeHUh?=
SK-MM-2	M4DvNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE[1[2JKSzVyPUCuOFM1PDJizszN	MWXTRW5ITVJ?
BOKU	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3PHXWlEPTB;MD60N\|c6OiEQvF2=	NYjnW4E5W0GQR1XS
NOMO-1	NG\odlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHn0WnhKSzVyPUCuOFM5PiEQvF2=	NWLBPGozW0GQR1XS
J-RT3-T3-5	MkLjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVe5cG5uUUN3ME2wMlQ1QDd6IN88US=>	MUfTRW5ITVJ?
COLO-668	M3PFNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkLRTWM2OD1yLkS1OlY5KM7:TR?=	M{DEO3NCVkeHUh?=
SF539	Mn3OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYfJR\|UxRTBwNEi2PFQh\|ryP	NW[4bZBlW0GQR1XS
LB2518-MEL	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofiTWM2OD1yLkS5O\|A{KM7:TR?=	M4fSPHNCVkeHUh?=
TE-441-T	NIDTSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NU[5NGQ{UUN3ME2wMlUxOTJizszN	M4qyRnNCVkeHUh?=
MDA-MB-134-VI	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{THPGlEPTB;MD61NFkzOSEQvF2=	NVrLU2ExW0GQR1XS
SCC-3	NVfTbYxET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHTqUZVKSzVyPUCuOVE5PzNizszN	MnXYV2FPT0WU
KLE	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnW5TWM2OD1yLkWyNVcyKM7:TR?=	MXrTRW5ITVJ?
LB2241-RCC	M{izdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV;JR\|UxRTBwNUK1NlUh\|ryP	NX\zRopuW0GQR1XS
NCI-H1417	MmrRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37yS2lEPTB;MD61N\|Q{PSEQvF2=	M1TGOnNCVkeHUh?=
NCI-H2081	NVLlWpNGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mo[1TWM2OD1yLkW4OlEyKM7:TR?=	MYHTRW5ITVJ?
NCI-H1522	MoHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYXqUmR7UUN3ME2wMlU6Ozh\|IN88US=>	M4jnVHNCVkeHUh?=
NCI-H889	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M37EdWlEPTB;MD61PVg1PCEQvF2=	MYHTRW5ITVJ?
CGTH-W-1	NHHi[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlyyTWM2OD1yLk[wO\|U2KM7:TR?=	MnewV2FPT0WU
EB-3	NUe3OoQyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXPJR\|UxRTBwNkGxOVMh\|ryP	Ml;0V2FPT0WU
D-336MG	NGLWb3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTBwNkG3PVEh\|ryP	M3zCPHNCVkeHUh?=
LC-1F	M{\JcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIPUOINKSzVyPUCuOlI2QTJizszN	M1\pRnNCVkeHUh?=
MHH-NB-11	Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn3YTWM2OD1yLk[zPFAyKM7:TR?=	MY\TRW5ITVJ?
SK-N-FI	M1LicGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHHTWM2OD1yLk[zPVEh\|ryP	M3\ZZ3NCVkeHUh?=
NCI-H69	NUfYfYRUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGi1TWhKSzVyPUCuOlQ5PzlizszN	NYn0UZpTW0GQR1XS
SCH	NYn1O4xvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIi5TWdKSzVyPUCuOlYxOjNizszN	M4fkVnNCVkeHUh?=
LS-513	NHe2OGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmnyTWM2OD1yLk[3NlU6KM7:TR?=	NGT5UGtUSU6JRWK=
CP67-MEL	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2DMcmlEPTB;MD62O\|U6PiEQvF2=	NXLCXY1LW0GQR1XS
GCIY	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYnJR\|UxRTBwN{CzOlMh\|ryP	MXLTRW5ITVJ?
SHP-77	NYXiTGtzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTBwN{C3N\|Qh\|ryP	MnzyV2FPT0WU
EHEB	NX7oUVdHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkXjTWM2OD1yLkexPFU1KM7:TR?=	NYL4XWlYW0GQR1XS
D-247MG	NG\6UJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\DTWM2OD1yLkezNlMzKM7:TR?=	MoXvV2FPT0WU
Raji	M3fPW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2nPemlEPTB;MD63OFk5QSEQvF2=	NFvFPIhUSU6JRWK=
MPP-89	NFvoVZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlKzTWM2OD1yLke1PVc5KM7:TR?=	M3:1bHNCVkeHUh?=
EKVX	Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGm4c\|ZKSzVyPUCuO\|kxPzNizszN	M4LOWnNCVkeHUh?=
HCC2218	NV76TGR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1P1RmlEPTB;MD63PVE{OSEQvF2=	NU\IS4ZEW0GQR1XS
KNS-81-FD	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHn1emFKSzVyPUCuPFExOTFizszN	MnLvV2FPT0WU
HCC2157	NWLFepRMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3z0eWlEPTB;MD64OFk2OSEQvF2=	NH[yT3JUSU6JRWK=
BT-474	Ml64S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4T3d2lEPTB;MD64PFg2PCEQvF2=	NFPMfFdUSU6JRWK=
NCI-H748	NGm2XXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1e0TmlEPTB;MD65NVIh\|ryP	NInUfFVUSU6JRWK=
EW-24	M13HV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrOTWM2OD1yLkmyNFAzKM7:TR?=	NYXMdmxtW0GQR1XS
D-263MG	M3vXd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3vYTGlEPTB;MD65OFUyOiEQvF2=	M3PCUHNCVkeHUh?=
OMC-1	M{jzbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzJR\|UxRTBwOU[zO\|Mh\|ryP	MnXqV2FPT0WU
NCI-H2196	M4jXW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIGySnNKSzVyPUCuPVc4PzdizszN	MorMV2FPT0WU
HAL-01	M4HIW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYO1W5h{UUN3ME2wMlk6QDd{IN88US=>	M2q2SXNCVkeHUh?=
NCI-H2107	M4K3bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWXGOZUyUUN3ME2xMlAyQDV2IN88US=>	NELZTWlUSU6JRWK=
LB996-RCC	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXi1bWxkUUN3ME2xMlA5ODVzIN88US=>	NFzBb5VUSU6JRWK=
NCI-H1395	MlzrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmX0TWM2OD1zLkGwOlch\|ryP	Mo\mV2FPT0WU
CHP-126	MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWPJR\|UxRTFwMU[xPVkh\|ryP	MofrV2FPT0WU
NB69	M3npdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX;IU2NmUUN3ME2xMlI3OTR6IN88US=>	NWXKeIw4W0GQR1XS
CAS-1	M332bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPte4RKSzVyPUGuN\|QzOzFizszN	MXLTRW5ITVJ?
JVM-3	M3P2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MUDJR\|UxRTFwNEe4OVUh\|ryP	MkjRV2FPT0WU
DMS-153	NYfKdVQzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn[yTWM2OD1zLkW3Olc1KM7:TR?=	Mm[4V2FPT0WU
SK-MEL-2	M2Tremdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPkTWM2OD1zLkexO\|g6KM7:TR?=	M1:wfHNCVkeHUh?=
NCI-H1155	NF\3UnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTFwN{O2O\|Yh\|ryP	MXnTRW5ITVJ?
NCI-H1092	NX;wNmd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoSwTWM2OD1zLke2NVgzKM7:TR?=	MmHpV2FPT0WU
LU-165	M4TIOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYPJR\|UxRTFwOE[0O\|Yh\|ryP	NV[zZVdKW0GQR1XS
HL-60	M3nOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DtO2lEPTB;MT65PVkxQCEQvF2=	NEO1bo9USU6JRWK=
REH	NWn2VJZnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4C2WmlEPTB;Mj6wNFU5OiEQvF2=	M3LkR3NCVkeHUh?=
JVM-2	NGDjbpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlLYTWM2OD1{LkC2NVM2KM7:TR?=	MVnTRW5ITVJ?
MN-60	NWjSTmZIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\RN2o{UUN3ME2yMlE4OzB6IN88US=>	NGXzSY5USU6JRWK=
SCC-15	NIPTZ4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\XR5JKSzVyPUKuNlAzPyEQvF2=	MnPhV2FPT0WU
SNU-C1	M1HPNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PicWlEPTB;Mj6yNVM1OyEQvF2=	M{fTe3NCVkeHUh?=
SK-MEL-1	MnL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmC1TWM2OD1{LkOyNFQ4KM7:TR?=	Mnf5V2FPT0WU
TGW	M3fXd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37tSmlEPTB;Mj6zOVAzPyEQvF2=	Mkn1V2FPT0WU
CA46	M4DJUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXXwTHNDUUN3ME2yMlc2QTZ5IN88US=>	MVzTRW5ITVJ?
NCI-H23	NHH4OIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGrsVJBKSzVyPUKuPFA4QTFizszN	MXnTRW5ITVJ?
MMAC-SF	Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTJwOE[2Nlgh\|ryP	NYqzU2lPW0GQR1XS
NCI-H2171	NVLtbI5mT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mne4TWM2OD1\|LkCzOFQ5KM7:TR?=	MoHzV2FPT0WU
A704	NXTI[IpvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTNwMUSxPVQh\|ryP	MV;TRW5ITVJ?
DB	MoHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWL4OGl5UUN3ME2zMlI2PTd4IN88US=>	M1vQOnNCVkeHUh?=
NCI-H719	NIPYRlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4TjcmlEPTB;Mz6zNFM5PCEQvF2=	MljJV2FPT0WU
MC-CAR	NWXKSXhbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTNwNUS4NVch\|ryP	NY\6dllzW0GQR1XS
SIMA	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoDLTWM2OD1\|LkW4OFE3KM7:TR?=	MoDzV2FPT0WU
SW872	M2Dwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4e4dWlEPTB;Mz63PFExOSEQvF2=	M1jRZ3NCVkeHUh?=
HCC1187	M3jENGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVrlT4NTUUN3ME2zMlc5OzF3IN88US=>	NYWySlFoW0GQR1XS
EW-13	M2HBSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2PSWWlEPTB;Mz64N\|QyPyEQvF2=	MVzTRW5ITVJ?
NCI-SNU-1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGiz[FBKSzVyPUSuNlE6QTlizszN	MlHIV2FPT0WU
NCI-H226	NFX2WmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFfVSWxKSzVyPUSuN\|M3ODZizszN	NYCzVIlOW0GQR1XS
RPMI-8866	M3vhSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX2zSWFSUUN3ME20MlM3ODJ7IN88US=>	M4HI[3NCVkeHUh?=
OCI-AML2	MoqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnrzTWM2OD12LkW1NlMh\|ryP	NF7MVnhUSU6JRWK=
LU-65	NF71fnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVL3PZRPUUN3ME20Mlk{ODN\|IN88US=>	Mn\qV2FPT0WU
SK-N-DZ	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2fQWGlEPTB;NT62N\|Q3PSEQvF2=	M1LZbHNCVkeHUh?=
NB14	NWnJdFlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIDne5RKSzVyPUWuPVcyOzVizszN	MXHTRW5ITVJ?
COLO-829	MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnv5TWM2OD14LkOzN\|U6KM7:TR?=	M2qweXNCVkeHUh?=
MHH-CALL-2	NEniR3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHGNFhkUUN3ME22MlUyPTB6IN88US=>	MkjpV2FPT0WU
NCI-H1770	NVPMe2pVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUSxNVVlUUN3ME22MlY3QTB2IN88US=>	NGryZoZUSU6JRWK=
ECC4	M1TE[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\HdphKSzVyPU[uPFIyPzlizszN	MmjLV2FPT0WU
A498	NUDZdJprT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\1TWM2OD14Lki3NVkzKM7:TR?=	MmXoV2FPT0WU
DMS-79	MnrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGHYVGVKSzVyPUeuNFQ2OTJizszN	MYXTRW5ITVJ?
P30-OHK	NEXJSZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTdwMkG5NFYh\|ryP	NXK2W\|hyW0GQR1XS
D-502MG	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYnrS5NzUUN3ME23Mlk5OzZizszN	NHLhVXNUSU6JRWK=
RCC10RGB	NXv5fZM{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmTkTWM2OD16LkC2Nlgh\|ryP	M4n6OnNCVkeHUh?=
U-698-M	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;rPWlEPTB;OD6yPVIzPiEQvF2=	MV;TRW5ITVJ?
BB49-HNC	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnm1TWM2OD17LkSyNlY2KM7:TR?=	M1G4WXNCVkeHUh?=
ES1	MlHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGi4WI5KSzVyPUmuOlg6PTZizszN	Mor6V2FPT0WU
MFM-223	MnrVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\GVnlpUUN3ME2xNE46QTJ5IN88US=>	NYHt[5ZHW0GQR1XS
C2BBe1	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHKyfHBKSzVyPUGxMlM2OjNizszN	MX7TRW5ITVJ?
EB2	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXHJR\|UxRTF{Lk[4PFEh\|ryP	M1vLdXNCVkeHUh?=
C8166	MkTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{DV[mlEPTB;MUOuPFMxOyEQvF2=	NXm2cZJVW0GQR1XS
ES3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MojXTWM2OD1zMz65PVc4KM7:TR?=	NGHubXpUSU6JRWK=
NCI-H1650	NXPBZmo3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTyVXd{UUN3ME2xOk4{PzZ3IN88US=>	MlvRV2FPT0WU
Mo-T	NIThRpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTF5LkSwNlkh\|ryP	NXrMRVNmW0GQR1XS
NB7	MkXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn;RTWM2OD1zNz63OFY4KM7:TR?=	NH\SUHJUSU6JRWK=
ES7	NVXsUoQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTF7LkW1NFch\|ryP	M2C1b3NCVkeHUh?=
ES5	NVfWU3FnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk\ZTWM2OD1{MT63OlcyKM7:TR?=	NFvRbmhUSU6JRWK=
MSTO-211H	MnSwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlriTWM2OD1{MT64PFU5KM7:TR?=	M33GZ3NCVkeHUh?=
U-87-MG	MmrpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTRWG1qUUN3ME2yOU4yQTZ4IN88US=>	M{HDeXNCVkeHUh?=
THP-1	M{\mZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoPWTWM2OD1{OT63NlAyKM7:TR?=	NUjkfXJLW0GQR1XS
NB10	MmjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TrRWlEPTB;M{CuNlY6PCEQvF2=	M3;aXXNCVkeHUh?=
NH-12	NVvSOIVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkLlTWM2OD1\|Mz6yNFE4KM7:TR?=	NUDLOIxUW0GQR1XS
COLO-824	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnfPTWM2OD1\|ND6xNFA3KM7:TR?=	MYrTRW5ITVJ?
SKM-1	M{HIfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlvUTWM2OD1\|Nz64OFIzKM7:TR?=	MYXTRW5ITVJ?
NCI-H1838	Mnf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3PvVWlEPTB;M{iuN\|c6PyEQvF2=	MmLOV2FPT0WU
RL	NVjRe3hpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmC2TWM2OD1\|OT6yOFc4KM7:TR?=	NWjNN2hFW0GQR1XS
COLO-800	M2i3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnfUTWM2OD12MD6wO\|c{KM7:TR?=	NVnQN497W0GQR1XS
KG-1	NYH1U2w5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHflWXVKSzVyPUSwMlg6PTVizszN	MVLTRW5ITVJ?
TUR	MmL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHHwUnhKSzVyPUSxMlY{QTlizszN	NI\SenpUSU6JRWK=
LNCaP-Clone-FGC	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4Hpd2lEPTB;NEGuPVAyPyEQvF2=	Mny0V2FPT0WU
NCI-H322M	NEjCeFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MV3JR\|UxRTR{LkW5PFQh\|ryP	NI\hZYpUSU6JRWK=
LNCaP	NIjpfXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUS1ToVuUUN3ME25NU4{KG6P	NGXXSmMzPTVyNUG3OC=>
C4-2	M2rXdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonKTWM2OD16IH7N	M1v1eVI2PTB3MUe0
JURKAT	MlTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MV6yOEBp		NHztOGpKSzVyPUSxOk43PiCwTR?=	MVmyOFUyQTl7NR?=
MOLT-4	NWjGc\|lZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2DOUFI1KGh?		MoXyTWM2OD1{OEWzMlUhdk1?	MVOyOFUyQTl7NR?=
REH	NF7mXohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NVnvdXN2OjRiaB?=		MX;JR\|UxRTJ6Nz62PEBvVQ>?	M{W3blI1PTF7OUm1
NALM-6	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MkXMNlQhcA>?		M3rSZWlEPTB;M{SzN\|Ahdk1?	MUOyOFUyQTl7NR?=
RS 4;11	NULYSIFuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUnrRnA4OjRiaB?=		Mki4TWM2OD13MUmuNFUhdk1?	NW\q[W1KOjR3MUm5PVU>
697	NV7T[WZJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUXQenJTOjRiaB?=		MoW0TWM2OD1{MUC3MlEhdk1?	M4nBblI1PTF7OUm1
SIL-ALL	MnnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MmP2NlQhcA>?		M{PzPGlEPTB;MUm5Mlc4KG6P	MVeyOFUyQTl7NR?=
CEM	NILlVJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NInsPIUzPCCq		NUPwRlFjUUN3ME21Nk4yQCCwTR?=	Mn;WNlQ2OTl7OUW=
P12	NWHsfVd2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NX21WWR5OjRiaB?=		MnHOTWM2OD1\|OT6yO{BvVQ>?	NUjselZEOjR3MUm5PVU>
NALM-16	NIrMTW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MkWwNlQhcA>?		NHXEVppKSzVyPUm2MlI5KG6P	M2XISVI1PTF7OUm1
JURKAT	MlTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3HEZ\|Q5KGh?		Mk\sTWM2OD1zND64OEBvVQ>?	NXPGNJhxOjR3MUm5PVU>
MOLT-4	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1PUc\|Q5KGh?		NFThboFKSzVyPUK2MlYhdk1?	MV6yOFUyQTl7NR?=
REH	MmrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEPrWFU1QCCq		NF;RSFdKSzVyPUS0MlcyKG6P	M1\RfVI1PTF7OUm1
NALM-6	MnHqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHfhcnc1QCCq		MmS5TWM2OD1{Mz6yOkBvVQ>?	M4i1ZlI1PTF7OUm1
RS 4;11	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M16xRlQ5KGh?		NV[2UFFCUUN3ME2xOlQvOjhibl2=	NGnSZmQzPDVzOUm5OS=>
697	M1v0OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXS0PEBp		MoLyTWM2OD1\|MEWuN{BvVQ>?	MUOyOFUyQTl7NR?=
SIL-ALL	MlTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXu0PEBp		Mlu3TWM2OD15ND62NkBvVQ>?	MVGyOFUyQTl7NR?=
CEM	MmixS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3zBR\|Q5KGh?		NYm2[IdMUUN3ME2yOE42PSCwTR?=	MVSyOFUyQTl7NR?=
P12	NYXYNVNST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M3vFWFQ5KGh?		M1TIfWlEPTB;MUiuOFYhdk1?	MWeyOFUyQTl7NR?=
NALM-16	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVi0PEBp		MofVTWM2OD14Mz6yOEBvVQ>?	MkOwNlQ2OTl7OUW=
JURKAT	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHLOW2g4OiCq		NIrzdo1KSzVyPUOuOlUhdk1?	Mmf3NlQ2OTl7OUW=
MOLT-4	MmnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MXK3NkBp		NIW1eFBKSzVyPUeuN\|khdk1?	M1HrdlI1PTF7OUm1
REH	NXewco9yT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{TvclczKGh?		MWLJR\|UxRTF4LkCxJI5O	M4[0blI1PTF7OUm1
NALM-6	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXe5eoJ{PzJiaB?=		NVvuW5o3UUN3ME2xMlc5KG6P	M3XTT\|I1PTF7OUm1
RS 4;11	NEHCbHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M2f5NFczKGh?		MlL3TWM2OD12LkO4JI5O	MWiyOFUyQTl7NR?=
697	NHPzTpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXm3NkBp		MYLJR\|UxRTd2LkK4JI5O	NELXVVczPDVzOUm5OS=>
SIL-ALL	MkOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NUnYNpVNPzJiaB?=		NHz5UGFKSzVyPUeuNkBvVQ>?	NG\ZXpAzPDVzOUm5OS=>
CEM	M3fVPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Ml32O\|IhcA>?		MoHSTWM2OD13LkSyJI5O	NXTDVHNzOjR3MUm5PVU>
P12	M17ib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{j6OFczKGh?		NGS2V4lKSzVyPU[uN\|chdk1?	M1vUfFI1PTF7OUm1
NALM-16	NX74RZFJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M{fXc\|czKGh?		MWTJR\|UxRTd5LkezJI5O	M{\qTVI1PTF7OUm1
Y79	NH\iZnBCeG:ydH;zbZMhSXO\|YYm=	Mny0NU02OCCwTR?=	M370TlEzNzJ2IHi=	MXXEUXNQ	NHv5NY9qdmS3Y3XkJIFxd3C2b4Ppd{B4cGmlaDDjZY4h[mViZX7oZY5k\WRiYomgTHQ>	NFO0ZVUzPDN4Nk[2OS=>
WER-Rb-1	NWXZfnk{SXCxcITvd4l{KEG\|c3H5	NHLXUG0yNTVyIH7N	MYSxNk8zPCCq	NHjn[VJFVVOR	M1;OO4lv\HWlZXSgZZBweHSxc3nzJJdpcWOqIHPhckBj\SCnbnjhcoNm\CCkeTDIWC=>	MVKyOFM3PjZ4NR?=
G7	NFviVFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUDoOJVqUUN3ME2zMlMhdk1?	NUfaNoZxOjR{MES3N\|M>
G166	NV7hbVdDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmXRTWM2OD15LkCgcm0>	Mli0NlQzODR5M{O=
CB660	M{[5N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LOR2lEPTB;Nj60JI5O	Mkf1NlQzODR5M{O=
CB1117	NH2zS\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWTzeZprUUN3ME2xOU43KG6P	NWT4R5dNOjR{MES3N\|M>
KB-3-1	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYPJR\|UxRTFwNEigxtEhOC53MzDuUS=>	NUT4PYxrOjN7NkK0OFU>
KB-8-5-11	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4i5dmlEPTB;NT6wNUDDuSB{LkCxJI5O	M2Hl[VI{QTZ{NES1
KB-C-1	NET3VJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTF4Lke2JOKyKDRwNUGgcm0>	MmPWNlM6PjJ2NEW=
KB-V-1	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mmr0TWM2OD1{OEGuNlQhyrFiM{GuOVchdk1?	NFTBZ2EzOzl4MkS0OS=>
OVCAR-8	NHv6enZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTdwMUmgxtEhOy54MDDuUS=>	MorRNlM6PjJ2NEW=
NCI-ADR-RES	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVLJR\|UxRTF{N{OuN\|AhyrFiMUmxMlIxKG6P	NEX3R4IzOzl4MkS0OS=>
MCF7	NFnS[IhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4qwVGlEPTB;NT6xNUDDuSBzLkS3JI5O	NVfDdJVnOjN7NkK0OFU>
MCF7-FLV1000	NEPyVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHP5b3lKSzVyPUO5N{4yQCEEsTC3OE45OyCwTR?=	MlPHNlM6PjJ2NEW=
S1	NWn1e2hvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYTycGZIUUN3ME2yOE4{OCEEsTC0Mlc2KG6P	NX7WR4hMOjN7NkK0OFU>
S1-M1-80	M{GydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFWyOo1KSzVyPUK2NU4xPiEEsTC0PE4zPSCwTR?=	M3PZSFI{QTZ{NES1
CORL-23/P	NFfjW3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2m3Z2lEPTB;ND6zPEDDuSBzLkK1JI5O	NInxXXIzOzl4MkS0OS=>
CORL-23/R	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TxZWlEPTB;NT6xOkDDuSBzLkizJI5O	NE[3VpIzOzl4MkS0OS=>
NIH3T3	NIDPRm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmW2TWM2OD12MD62NEDDuSB2Lkm3JI5O	MkXONlM6PjJ2NEW=
NIH3T3-G185	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHGTWM2OD1{NEGzMlQxKMLzIESyN{43PiCwTR?=	NUPCU5J3OjN7NkK0OFU>
pcDNA-HEK293	NXLQNXFvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFXtc5BKSzVyPUKuO\|UhyrFiMD62O{BvVQ>?	MmDFNlM6PjJ2NEW=
MDR19-HEK293	NXvzNYt[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3q3UWlEPTB;OEWuOVAhyrFiMUOuOlchdk1?	NEP4OJczOzl4MkS0OS=>
R482-HEK293	NHLUU\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml:xTWM2OD1{NT65O{DDuSB2Lkm1JI5O	NIXHT4szOzl4MkS0OS=>
MRP1-HEK293	M1rJ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mof2TWM2OD1{Lkm5JOKyKDFwNEmgcm0>	MUmyN\|k3OjR2NR?=
SF188	NH;iUoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1fRZ\|ExNTFyMDDuUS=>	NU\pTYdWOjRvOU[gbC=>	MYLEUXNQ	NH3tdG9qdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMUBl\XCnZHXueEBu[W6wZYK=	M3u0XFI{QDh5NkS1
T98G	NHr1VHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUT5RWdZOTBvMUCwJI5O	M1H1WFI1NTl4IHi=	Mn7WSG1UVw>?	MYHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiClb37j[Y51emG2aX;uMUBl\XCnZHXueEBu[W6wZYK=	M2nDclI{QDh5NkS1
DU145	NXz3RVUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			NVjUXnczTE2VTx?=	NGLTTI1KSzVy4pk8OlAhdk1?	M{DxSFI{QDh2NEK4
LNCaP	NUXGO2lUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MWfEUXNQ	MljvTWM2OOLKvEe1JI5O	M2DW[\|I{QDh2NEK4
PC3	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NFr1TI5FVVOR	M33z[2lEPTEkiMyxO\|Uhdk1?	M2iydFI{QDh2NEK4
RT4	NYLWWItPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mm\ITWM2OD1{Nz6yNUBvVQ>?	NWW5bWJLOjN5OUK2N\|k>
5637	Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEL3cYtKSzVyPUS1MlQ4KG6P	NF62bVQzOzd7Mk[zPS=>
T24	NEXMXolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFn3epNKSzVyPUe5MlEzKG6P	MYGyN\|c6OjZ\|OR?=
MCF7	NX:1W\|FSTnWwY4Tpc44hSXO\|YYm=	MXWxNFAhdk1?	MkLMNUBp	MV\EUXNQ	M{DEd5Jm\HWlZYOgeIhmKGmwZIXjeIlwdiCxZtMgS5Jm[jFuwrDT[4syNMLiUIOyMOKhW2W{cHnuZVMtKGGwZNMgW4l{eDJ?	MmnlNlM4PzB{NES=
KB-V1	NXXUW\|lGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofITWM2OD1\|LkmyJO69VQ>?	M4TuS\|I{PTl\|MUm2
Hec50co	NVz1dmY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDT[HVGUUN3ME21JI5O	Mk[2NlMyPDZ4OEe=
MDA-MB-468	NGL3N41CeG:ydH;zbZMhSXO\|YYm=	NITqcHgyNzVxMUCgcm0>	NGX5XWEzPC92OD:3NkBp	NVPoR5o6TE2VTx?=	M3y0OIlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MmPGNlMyPDR{OUS=
MCF10A	M{fESWFxd3C2b4Ppd{BCe3OjeR?=	NHfpW\|IyNzVxMUCgcm0>	NUThbIZQOjRxNEivO\|IhcA>?	NIXIelVFVVOR	M4DwTYlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NYLzenNwOjNzNESyPVQ>
Huh-7	M3jkS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWLKdY1WOS9zMD:xNFAwOTByMDDuUS=>	MlLSOFghcA>?		MYTk[YNz\WG\|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIRwe2VvZHXw[Y5l\W62bIm=	Ml:0NlI4PDV3OEe=
Daoy	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mni4NU45PzVvMkSwJI5O	NXf2WoxtPzJiaB?=	MljhSG1UVw>?	NXK5T2JOUUN3ME21JI5O	NYrQWZRGOjJ\|OUCyO\|k>
ONS-76	NVPHc5V4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXRXYNqOS56N{WtNlQxKG6P	NYHMV5dQPzJiaB?=	MoXMSG1UVw>?	MmGxTWM2OD15LkWgcm0>	Ml;TNlI{QTB{N{m=
SUM 149	M{S2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVrYe\|loOC1zMECgcm0>	M2e4UFczKGh?		MUnpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK=	M1HFV\|IzOzB7OUO5
MDA-MB-231	NIDlO2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1naUVAuOTByIH7N	MVe3NkBp		Ml;nbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnHy	M3XkU\|IzOzB7OUO5
HR5	M4DrfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVSwMVExOCCwTR?=	M3\0RlczKGh?		MmLsbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnHy	Mln6NlI{ODl7M{m=
BT-474-M1	NYnHOmluT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3fvW\|AuOTByIH7N	MV[3NkBp		NYDjbnB4cW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz	NHvkZpMzOjNyOUmzPS=>
AU565	M2TWW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXOwMVExOCCwTR?=	M2\xSFczKGh?		Mn7WbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnHy	NHXTT4EzOjNyOUmzPS=>
T47D	MnfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUOwMVExOCCwTR?=	NVzIeHJ5PzJiaB?=		MliybY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnHy	NVi2bIFoOjJ\|MEm5N\|k>
MCF7	NX\1d2JQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NETnW2IxNTFyMDDuUS=>	NW\te4Y{PzJiaB?=		NVm3RmNqcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz	NEHKRlIzOjNyOUmzPS=>
HCT116p53(+/+)	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{P4cVExNTFyMECgcm0>	MlzCNlQwPDhiaB?=		NYXUcGtrcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGOxbYDs[ZRmdHliYYSgNlUhdk1?	M4rUOVIzOjZ{MUex
HCT116p53(-/-)	MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{jQWFExNTFyMECgcm0>	NX:yfJBXOjRxNEigbC=>		NWn2SGlXcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGOxbYDs[ZRmdHliYYSgNlUhdk1?	M{fmVlIzOjZ{MUex
HeLa	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2ezUlExNTFyMDDuUS=>	M4jmRVQ5KGh?	M4HRWmROW09?	MmXwTWM2OD13Mj65JI5O	NHnJdIgzOjB6MEKzOS=>
HeLa	Mm[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFvyfXEyOC1zMECgcm0>	M1\ke\|czKGh?	NHv4[IRFVVOR	M1\o[2lEPTB;NUCuOUBvVQ>?	MX:yNlA5ODJ\|NR?=
GBC	NYC1WXdOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NEPnSGQ4OiCq		M17WUmlEPTB;MUSuO\|ghdk1?	MWGyNVk3PTd\|OR?=
GB-CL-1	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MWS3NkBp		MUnJR\|UxRTVwMkKgcm0>	M{\KRVIyQTZ3N{O5
Mz-ChA-2	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NGX4eJM4OiCq		MniyTWM2OD1\|LkOxJI5O	NXqzNJpVOjF7NkW3N\|k>
TGBC1-TKB	NInCR\|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MlHCNVQ1KGh?		MYnJR\|UxRTZwN{Kgcm0>	NWHBTFBGOjF7NkW3N\|k>
Wittier	NYjqdnFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		M2THd\|czKGh?		MXLJR\|UxRTNwMk[gcm0>	MnrqNlE6PjV5M{m=
H-1	Mlj0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MYi3NkBp		NG\wdmZKSzVyPUmuOVQhdk1?	M4PxVVIyQTZ3N{O5
HuH-28	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MnjtO\|IhcA>?		MmnBTWM2OD1zMT6xPUBvVQ>?	NIjxRlEzOTl4NUezPS=>
NEC	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1vqWFczKGh?		Mm\ITWM2OD17Lkm4JI5O	NHjtNGwzOTl4NUezPS=>
REB	MnnRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVK3NkBp		MXLJR\|UxRTF\|LkWxJI5O	NIjVVVkzOTl4NUezPS=>
CC-LP-1	MnH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NITMeFY4OiCq		MlH6TWM2OD13Lki0JI5O	NXK0PFdSOjF7NkW3N\|k>
CC-SW-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NG\wW3c4OiCq		MnS3TWM2OD17LkW1JI5O	NGq0bGozOTl4NUezPS=>
EGI-1	M3LRW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MV23NkBp		NXnFb4l{UUN3ME2xNE44OiCwTR?=	NF\6T5kzOTl4NUezPS=>
Sk-ChA-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M3fweFczKGh?		MmXHTWM2OD1zNz6yJI5O	NFPocVIzOTl4NUezPS=>
TFK-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MoTRO\|IhcA>?		NIfHfY1KSzVyPUGzMlQ2KG6P	NGTjZnMzOTl4NUezPS=>
786-O	NGHBW3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLpb\|VzPS16MDDuUS=>	NWf0VYF6QTZiaB?=	NUnsWVNYUEOu	NW\kXXpLe3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7N	MoTBNlE3PDJ\|N{S=
A498	MlPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{\INlUuQDBibl2=	M1K0eVk3KGh?	MmXLTGNt	NFPtUYt{fXCycnXzd4V{KHSqZTDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKHerdHigTWM2OMLidnHseYV{KG:oIEKgeI8hOjBibl2=	Mn;oNlE3PDJ\|N{S=
ACHN	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYi1MVgxKG6P	NEjJO5k6PiCq	M2LYNmhEdA>?	NXPKN5Fwe3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7N	NE\DVJQzOTZ2MkO3OC=>
Caki-1	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrCV\|J2PS16MDDuUS=>	NXXzcJRUQTZiaB?=	MlnZTGNt	M{LzS5N2eHC{ZYPz[ZMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIhf2m2aDDJR\|UxyqC4YXz1[ZMhd2ZiMjD0c{AzOCCwTR?=	NYroOHZ3OjF4NEKzO\|Q>
SN12C	NUXwd\|B3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2O2bFUuQDBibl2=	MWO5OkBp	Mn7RTGNt	NV:xVWJ{e3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7N	MXiyNVY1OjN5NB?=
HMC-1.1	MmHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3\0UFEuOTByMDDuUS=>	NVjHU5diPzJiaB?=		NI\MRmpqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmV?	M{LOeFIyOjR{MUi5
HMC-1.2	NFWwWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWWxMVExODBibl2=	MVK3NkBp		NGPlbFhqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmV?	NIrMVGQzOTJ2MkG4PS=>
C2	M33KN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFn0XHIyNTFyMECgcm0>	M2TaPFczKGh?		M1fxZ4lvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\Q>?	NV7DWIpmOjF{NEKxPFk>
CHP-212	Mm\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDIcpgyNTF{NTDuUS=>	MUmyOE0yOjBiaB?=		NEeycZZqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	NILqb2QzOTF4OUK0Ni=>
IMR-32	NXPlfoVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1vSSlEuOTJ3IH7N	NIfJfXIzPC1zMkCgbC=>		MnrXbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?=	NGXGUVQzOTF4OUK0Ni=>
Kelly	NFf6WFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIi3c4IyNTF{NTDuUS=>	NVK5WJY4OjRvMUKwJIg>		M13DU4lvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW=	NHvLTHYzOTF4OUK0Ni=>
SH-EP	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEHke5AyNTF{NTDuUS=>	MV6yOE0yOjBiaB?=		M3XMbYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW=	MWmyNVE3QTJ2Mh?=
SH-SY5Y	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXOxMVEzPSCwTR?=	NXnQO\|NoOjRvMUKwJIg>		NUTSe3ZkcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=>	NVfhUlR3OjFzNkmyOFI>
SK-N-AS	NVL5[oh3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4\NV\|EuOTJ3IH7N	MnuyNlQuOTJyIHi=		M3i0OolvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW=	MmWyNlEyPjl{NEK=
SK-N-BE	NXH3WmF6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2TqdlEuOTJ3IH7N	MorYNlQuOTJyIHi=		MlPBbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?=	MnLUNlEyPjl{NEK=
KG1	NXe5WVFLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGLUVlMyNzFyL{GwNEBvVQ>?	M4Lzb\|czKGh?	NIfNWWhFVVOR	NYK2VWROcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbjDpckBjd3SqIITpcYUuKGGwZDDkc5NmNWSncHXu[IVvfCCvYX7u[S=>	NWLuSYoyOTl2NUizOVg>
U937	NWXuT5lJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4LmclEwOTBxMUCwJI5O	M4PjdlczKGh?	MULEUXNQ	NGfFd4RqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	MYSxPVQ2QDN3OB?=
CAL62	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTUUnZkOC5zLUGwNEBvVQ>?	MmnCO\|IhcA>?	MoX4SG1UVw>?	MoTHSWM2OD1zLkSgcm0>	NYGyW214OTl{MkO1OVM>
OCUT-1	Mn\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1Ts[lAvOS1zMECgcm0>	MmL4O\|IhcA>?	M2Dlb2ROW09?	M2jxZmVEPTB;Mj6zJI5O	MV:xPVIzOzV3Mx?=
8505C	NXHK[XdCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIryV2sxNjFvMUCwJI5O	NX3iVndNPzJiaB?=	NEnxOJJFVVOR	NUHJdGdwTUN3ME2zMlIhdk1?	NXLXT21mOTl{MkO1OVM>
ACT-1	M2XYOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPQNE4yNTFyMDDuUS=>	MVK3NkBp	NFfldpZFVVOR	MmHBSWM2OD13LkSgcm0>	NEf6e2QyQTJ{M{W1Ny=>
SW1736	NVTYcGdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnzyNE4yNTFyMDDuUS=>	MVy3NkBp	NYDHe3J1TE2VTx?=	MmrSSWM2OD13Lk[gcm0>	MoDoNVkzOjN3NUO=

... Click to View More Cell Line Experimental Data

In vivo

BI 2536 given i.v. once or twice per week is highly efficacious in diverse xenograft models with acceptable tolerability by inhibiting cell proliferation through a mitotic arrest, and subsequently induction of tumor-cell death. Administration of BI 2536 at 50 mg/kg once or twice per week significantly inhibits growth of HCT 116 xenografts with T/C of 15% and 0.3%, respectively. BI 2536 treatment twice-weekly also leads to excellent tumor-growth in BxPC-3 and A549 models with T/C of 5% and 14%, respectively. ^[1]

Protocol

Kinase Assay:^[1]	+ Expand Plk1 in vitro kinase assay: Recombinant human Plk1 (residues 1-603) is expressed as N-terminal, GST-tagged fusion protein with a baculoviral expression system and purified by affinity chromatography with Glutathione-agarose. Enzyme activity assays for Plk1 are performed in the presence of serially diluted BI 2536 with 20 ng of recombinant kinase and 10 μg casein from bovine milk as the substrate. Kinase reactions are performed in a final volume of 60 μL for 45 minutes at 30 °C (15 mM MgCl₂, 25 mM MOPS [pH 7.0], 1 mM DTT, 1% DMSO, 7.5 mM ATP, 0.3 μCi γ-³³P-ATP). Reactions are terminated by the addition of 125 μL of ice-cold 5% TCA. After transfer of the precipitates to Multi-Screen mixed ester cellulose filter plates, plates are washed with 1% TCA and quantified radiometrically. Dose-response curve is used for calculating IC50 value.
Cell Research:^[1]	+ Expand Cell lines: HeLa, A43, SKOV-3, HT-29, K562, A549, Saos-2, MCF7, HCT116, COLO 205, Hep G2, Raji and PC-3 cells, etc. Concentrations: Dissolved in DMSO, final concentrations ~1 μM Incubation Time: 24 and 72 hours Method: Cells are exposed to various concentrations of BI 2536 for 24, and 72 hours. Cell growth is assessed by the measurement of Alamar Blue dye conversion in a fluorescence spectrophotometer. For determining the DNA content of the cultures, cell suspensions are fixed in 80% ethanol, treated for 5 minutes with 0.25% Triton X-100 in PBS, and incubated with 0.1% RNase and 10 μg/mL propidium iodide (PI) in PBS for 20 minutes at RT. Cell-cycle profiles are determined by flow cytometric analysis. (Only for Reference)
Animal Research:^[1]	+ Expand Animal Models: Female BomTac:NMRI-Foxn1^nu mice injected subcutaneously with HCT 116, NCI-H460, or A549 cells Formulation: Formulated in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl Dosages: ~50 mg/kg Administration: Injection i.v. once or twice per week (Only for Reference)

References

Solubility (25°C)

In vitro	Ethanol	100 mg/mL (191.69 mM)
	DMSO	21 mg/mL (40.25 mM)
	Water	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG 400+0.5% Tween 80+5% Propylene glycol For best results, use promptly after mixing.	15mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download BI 2536 SDF

Molecular Weight	521.66
Formula	C₂₈H₃₉N₇O₃
CAS No.	755038-02-9
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	N/A

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00526149	Completed	Breast Cancer\|Endometrial Cancer\|Head and Neck Cancer\|Melanoma (Skin)\|Ovarian Cancer\|Sarcoma	European Organisation for Research and Treatment of Cancer - EORTC	July 2007	Phase 2
NCT00526149	Completed	Breast Cancer\|Endometrial Cancer\|Head and Neck Cancer\|Melanoma (Skin)\|Ovarian Cancer\|Sarcoma	European Organisation for Research and Treatment of Cancer - EORTC	July 2007	Phase 2
NCT02215044	Terminated	Pancreatic Neoplasms	Boehringer Ingelheim	June 2007	Phase 1
NCT02215044	Terminated	Pancreatic Neoplasms	Boehringer Ingelheim	June 2007	Phase 1
NCT00412880	Completed	Carcinoma Small Cell	Boehringer Ingelheim	January 2007	Phase 2
NCT00412880	Completed	Carcinoma Small Cell	Boehringer Ingelheim	January 2007	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
We need to use BI 2536 in preclinical studies using mice, how to formulate the inhibitor for this in vivo study?
Answer:
For in vivo study, DMSO should not be more than 5% because the toxicity. You can formulated BI2536 in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl for animal study according to the reference :( Supplemental Data) http://linkinghub.elsevier.com/retrieve/pii/S0960-9822(06)02671-6

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

Selective Plk Inhibitors

GSK461364 : Plk1-selective, K_i=2.2 nM.
Plk Inhibitor in Clinical Trial

Rigosertib (ON-01910) : Phase III for Myelo Dysplastic Syndrome (MDS).
Newest Plk Inhibitor

Ro3280 ^New : Potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.
Calssic Plk Inhibitor

Volasertib (BI 6727) : Highly potent Plk1 inhibitor with IC50 of 0.87 nM and in phase II trials.

Related PLK Products4

SBE 13 HCl ^New

SBE 13 HCl is a potent and selective PLK1 inhibitor with IC50 of 200 pM, >4000-fold selectivity over Aurora A kinase, Plk2 and Plk3.
Ro-3306 ^New

RO-3306 is an ATP-competitive, and selective CDK1 inhibitor with K_i of 20 nM, >15-fold selectivity against a diverse panel of human kinases.
CCG-1423 ^New

CCG-1423 is a specific RhoA pathway inhibitor, which inhibits SRF-mediated transcription.
Rigosertib (ON-01910)

Rigosertib (ON-01910) is a non-ATP-competitive inhibitor of PLK1 with IC50 of 9 nM in a cell-free assay. It shows 30-fold greater selectivity against Plk2 and no activity to Plk3. Phase 3.
HMN-214

HMN-214 is a prodrug of HMN-176, which alters the cellular spatial orientation of Plk1.
GSK461364

GSK461364 inhibits purified Plk1 with K_i of 2.2 nM in a cell-free assay. It is more than 1000-fold selective against Plk2/3. Phase 1.

Features:Demonstrates >390-fold selectivity for Plk1 relative to Plk2 and Plk3.
Volasertib (BI 6727)

Volasertib (BI 6727) is a highly potent Plk1 inhibitor with IC50 of 0.87 nM in a cell-free assay. It shows 6- and 65-fold greater selectivity against Plk2 and Plk3. Phase 3.

Features:A high volume of distribution, indicating good tissue penetration, and a long terminal half-life.
MLN0905

MLN0905 is a potent inhibitor of PLK1 with IC50 of 2 nM.
Ro3280

RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.

Features:A selective PLK1 inhibitor. Demonstrates greater potency than BI2536. Potential use in nasopharyngeal carcinomas.
NMS-P937 (NMS1286937)

NMS-P937 (NMS1286937) is an orally available, selective Polo-like Kinase 1 (PLK1) inhibitor with IC50 of 2 nM, 5000-fold selectivity over PLK2/PLK3. Phase 1.

Choose Your Country or Region

By Signaling Pathways

By product type

BI 2536

Cited by 56 Publications

13 Customer Reviews

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BI 2536 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

Related PLK Products4

Choose Your Country or Region

By Signaling Pathways

By product type

BI 2536

Cited by 56 Publications

13 Customer Reviews

Purity & Quality Control

Choose Selective PLK Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download BI 2536 SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-03-27)

Tech Support

Frequently Asked Questions

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

Related PLK Products4

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)